141
Participants
Start Date
July 7, 2023
Primary Completion Date
March 26, 2024
Study Completion Date
June 24, 2024
Afrezza
Pharmaceutical form: powder Route of administration: inhalation
insulin degludec
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Rapid-acting Insulin Analog
Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Basal Insulin
Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Mount Sinai Diabetes Center, New York
Endocrine Associate of West Village, PC, Long Island City
SUNY Upstate Medical University, Syracuse
Mountain State Diabetes, Parkersburg
University of North Carolina at Chapel Hill, Chapel Hill
Atlanta Diabetes Associates, Atlanta
Iowa Diabetes Research, West Des Moines
Mayo Clinic, Rochester
Northwestern University Division of Endocrinology, Metabolism and Molecular Medicine, Chicago
The University of Texas Southwestern Medical Center, Dallas
Diabetes and Glandular Disease Clinic, P.A., San Antonio
Texas Diabetes & Endocrinology, P.A., Austin
Barbara Davis Center, Aurora
Las Vegas Endocrinology, Henderson
Loma Linda University-Diabetes Treatment Center, Loma Linda
Sansum Diabetes Research, Santa Barbara
University of Washington Diabetes Institute, Seattle
Boston Medical Center, Boston
Joslin Diabetes Center, Boston
Lead Sponsor
Collaborators (1)
Jaeb Center for Health Research
OTHER
Mannkind Corporation
INDUSTRY